<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between June 1986 and November 1994, 22 previously transfused patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) were treated with high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) (50 mg/kg over 4 consecutive days) and 7 Gy total lymphoid irradiation (TLI) in two fractions before allogeneic bone marrow transplantation (BMT) from HLA-identical sibling </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host-disease</z:e> (GVHD) prophylaxis included the combination of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> A in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="2" pm="."><plain>Actuarial survival at 5 years is 73 +/- 9 per cent for the entire group and 86 +/- 13 per cent for the seven patients &lt; or = 18 years </plain></SENT>
<SENT sid="3" pm="."><plain>The incidence of graft failure was 0 per cent, and of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 31.5 per cent and 24 per cent respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Prolonged interval from diagnosis to BMT adversely influenced survival (P = 0.03) </plain></SENT>
<SENT sid="5" pm="."><plain>No <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> have been documented in this series </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings indicate that survival with CY-TLI is comparable to that obtained using preparative regimens without radiation </plain></SENT>
<SENT sid="7" pm="."><plain>The changing role of radiotherapy in pretransplant immunosuppression for SAA is discussed </plain></SENT>
</text></document>